免疫遗传公司(纳斯达克代码：IMGN)被分析师平均建议持有

ImmunoGen, Inc. (NASDAQ:IMGN – Get Rating) has earned an average rating of "Hold" from the six ratings firms that are presently covering the company, Marketbeat.com reports. Three research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $10.25.

IMGN has been the topic of several recent analyst reports. Royal Bank of Canada cut shares of ImmunoGen from an "outperform" rating to a "sector perform" rating and cut their price target for the company from $9.00 to $6.00 in a report on Monday, March 21st. StockNews.com upgraded shares of ImmunoGen from a "sell" rating to a "hold" rating in a report on Tuesday, May 10th.

Get

ImmunoGen

alerts:

Shares of NASDAQ IMGN opened at $4.90 on Wednesday. ImmunoGen has a 52 week low of $3.10 and a 52 week high of $7.77. The firm's fifty day moving average is $4.03 and its 200 day moving average is $5.10. The company has a market cap of $1.08 billion, a price-to-earnings ratio of -8.17 and a beta of 0.98.

ImmunoGen (NASDAQ:IMGN – Get Rating) last issued its earnings results on Friday, May 6th. The biotechnology company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.11. ImmunoGen had a negative net margin of 140.30% and a negative return on equity of 82.39%. The company had revenue of $38.10 million for the quarter, compared to the consensus estimate of $20.84 million. During the same period in the previous year, the firm earned ($0.17) earnings per share. The firm's revenue for the quarter was up 142.7% on a year-over-year basis. As a group, equities analysts predict that ImmunoGen will post -0.86 EPS for the current year.

Several hedge funds have recently made changes to their positions in the company. Bank of America Corp DE boosted its holdings in shares of ImmunoGen by 34.7% during the 1st quarter. Bank of America Corp DE now owns 1,460,432 shares of the biotechnology company's stock valued at $6,951,000 after buying an additional 376,567 shares in the last quarter. Walleye Capital LLC raised its position in shares of ImmunoGen by 102.9% in the 1st quarter. Walleye Capital LLC now owns 56,516 shares of the biotechnology company's stock worth $269,000 after purchasing an additional 28,656 shares during the last quarter. Point72 Hong Kong Ltd raised its position in shares of ImmunoGen by 3,959.2% in the 1st quarter. Point72 Hong Kong Ltd now owns 32,798 shares of the biotechnology company's stock worth $156,000 after purchasing an additional 31,990 shares during the last quarter. RA Capital Management L.P. raised its position in shares of ImmunoGen by 7.4% in the 1st quarter. RA Capital Management L.P. now owns 21,741,458 shares of the biotechnology company's stock worth $103,489,000 after purchasing an additional 1,500,000 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd purchased a new position in shares of ImmunoGen in the 1st quarter worth about $229,000. Hedge funds and other institutional investors own 87.45% of the company's stock.

ImmunoGen Company Profile (Get Rating)

ImmunoGen, Inc, a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm.

Featured Stories

• Get a free copy of the StockNews.com research report on ImmunoGen (IMGN)
• Looking to Dump These 3 Possible Delisted Chinese Stocks? Let's Take a Look.
• Get Defensive With These Three Upgrades
• 3 Home Improvement Stocks That Can Renovate Your Portfolio
• Vera Bradley Stock Getting Cheap
• 3 Education Stocks to Enroll in This Summer

Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.